Predicting early outcomes in patients with intermediate- and high-risk prostate cancer using prostate-specific membrane antigen positron emission tomography and magnetic resonance imaging.

MLA

Meijer, Dennie, et al. “Predicting Early Outcomes in Patients with Intermediate- and High-Risk Prostate Cancer Using Prostate-Specific Membrane Antigen Positron Emission Tomography and Magnetic Resonance Imaging.” BJU International, vol. 129, no. 1, Jan. 2022, pp. 54–62. EBSCOhost, https://doi.org/10.1111/bju.15492.

APA

Meijer, D., van Leeuwen, P. J., Donswijk, M. L., Boellaard, T. N., Schoots, I. G., van der Poel, H. G., Hendrikse, H. N., Oprea-Lager, D. E., & Vis, A. N. (2022). Predicting early outcomes in patients with intermediate- and high-risk prostate cancer using prostate-specific membrane antigen positron emission tomography and magnetic resonance imaging. BJU International, 129(1), 54–62. https://doi.org/10.1111/bju.15492

Chicago

Meijer, Dennie, Pim J van Leeuwen, Maarten L Donswijk, Thierry N Boellaard, Ivo G Schoots, Henk G van der Poel, Harry N Hendrikse, Daniela E Oprea-Lager, and André N Vis. 2022. “Predicting Early Outcomes in Patients with Intermediate- and High-Risk Prostate Cancer Using Prostate-Specific Membrane Antigen Positron Emission Tomography and Magnetic Resonance Imaging.” BJU International 129 (1): 54–62. doi:10.1111/bju.15492.